Bufotenin: A Promising New Treatment for Depression

Depression rates in the United States are alarmingly high, affecting approximately one in six adults. For many, traditional treatments, including therapy and conventional antidepressants, have proven inadequate, with nearly 30% of individuals resorting to multiple medications without relief.

As research into mental health treatment evolves, several innovative approaches are being explored. Among these is bufotenin, a psychedelic compound derived from the skin of specific toads, including the Sonoran Desert toad.

The Origins of Bufotenin

Bufotenin (5-MeO-DMT) is chemically related to serotonin and is present in the skin, venom, and eggs of certain toads. Notably, pharmaceutical company AtaiBeckley, backed by Eli Lilly, is investigating a synthetic version of this compound as a potential treatment for depression. Current clinical trials for this nasal spray are at phase 2b, showing positive preliminary outcomes.

Clinical Trial Findings

A recent study involving 193 adults aged 18 to 75, all suffering from treatment-resistant depression, explored the effectiveness of various doses of bufotenin. Participants, who had previously tried at least two different antidepressants without satisfactory results, received supportive psychological care before, during, and after their collection of doses.

• 34% of participants experienced significant improvements with both the low (8 mg) and high (12 mg) doses.
• The low dose of 8 mg led to a notable average reduction of 12 points on a 60-point depression scale.
• Approximately 25% of those in the 8 mg group achieved remission from their depressive symptoms after just one treatment, meaning their scores fell below the threshold for clinical depression.
• Effectiveness was observed as early as day two, with benefits lasting for up to 57 days.

Potential Advantages and Side Effects

The rapid onset of effects is a crucial advantage of bufotenin. Unlike psilocybin or LSD, which may require over six hours to take effect, many patients receiving bufotenin are discharged within two hours. In contrast, FDA-approved esketamine also requires at least two hours for administration.

However, side effects were reported by a majority of participants, with 76% of those on the 8 mg dose and 85% on the 12 mg dose experiencing mild to moderate adverse events, including:

• Nasal discomfort
• Nausea
• Headaches
• Vomiting
• Tingling sensations
• Excessive saliva

This trial, a phase 2b study, is a pivotal step in establishing the safety and efficacy of bufotenin before proceeding to larger phase 3 trials required for regulatory approval.

Outlook on Depression Treatment

Beyond bufotenin, other psychedelics like psilocybin and LSD are also being researched as potential treatments for depression, with some currently in phase 3 clinical trials. The developments in psychedelic therapy hold promise, especially for those who have found no relief from standard antidepressant medications.